Clinical trials: Dasatinib
Leukemia, Lymphoblastic, Acute
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Philadelphia-chromosome-positive or partial ph-like acute lymphoblastic leukemia (ALL) preferred chemotherapy combined with tyrosine kinase inhibitors (TKIS) therapy.
- Trial name
- NCT03331211
- Testing
- TKIs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lung Cancer
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with advanced lung cancer that…
- Trial name
- NCT00570401
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dasatinib, BCR-ABL
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia (CML).
- Conditions
- Dasatinib, BCR-ABL, Chronic Myeloid Leukemia
- Trial name
- NCT04155411
- Testing
- Dasatinib
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Shenzhen Second People's Hospital
Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
This phase II trial studies how well dasatinib works in treating patients with chronic lymphocytic leukemia (CLL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia
- Trial name
- NCT01441882
- Testing
- Dasatinib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Myeloma
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560352
- Testing
- Dasatinib, Bortezomib, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
The goal of this clinical research study is to learn if dasatinib can help prevent breast cancer from developing in the unaffected breast.
- Trial name
- NCT01471106
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
Radiation and androgen deprivation is a common modality for patients with localized prostate cancer. Unfortunately for patients with intermediate to high risk prostate cancer incomplete tumor eradication and subsequent relapse…
- Trial name
- BrUOGPR255 (NCT01826838)
- Testing
- Dasatinib
- Sponsor
- Brown University
Chronic Myeloid Leukemia
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib)…
- Trial name
- NCT01073436
- Testing
- Discontinuation of therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cholangiocarcinoma
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.
- Trial name
- NCT02428855
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01620216
- Testing
- Antitumor Drug Screening Assay, Dasatinib, Idelalisib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Breast Cancer
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.
- Trial name
- NCT00754325
- Testing
- Dasatinib, Fulvestrant
- Where
- 28 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Refractory Solid Tumors, Pancreatic Adenocarcinoma
A Phase I/Expansion Study of Dasatinib
The purpose of this study is to find the highest dose of the drugs gemcitabine and dasatinib that can be given for the treatment of pancreatic cancer. Gemcitabine (also called Gemzar™)is a drug that is given intravenously.
- Trial name
- Gem/Dsat (NCT00598091)
- Testing
- gemcitabine, dasatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
This study is an extension study (prospective observational study) of 'IDEAL' study (A Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular Response in Newly Diagnosed Patients with…
- Trial name
- IDEAL-E (NCT02421926)
- Testing
- IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)
- Where
- 12 sites in South Korea
- Sponsor
- Asan Medical Center
Chronic Myeloid Leukemia
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on…
- Trial name
- NCT01627132
- Testing
- Dasatinib
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Shimousa Hematology Study Group
Tumors
Study of Dasatinib in Patients With Advanced Solid Tumors
The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.
- Trial name
- NCT00162214
- Testing
- Dasatinib + Ketoconazole
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant…
- Trial name
- NCT01030718
- Testing
- dasatinib
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
This study aims at exploring the activity of a frontline approach based on dasatinib plus steroids administration as induction treatment, followed by the infusion of Blinatumomab, in adult Ph+ ALL.
- Trial name
- NCT02744768
- Testing
- Dasatinib, Blinatumomab
- Where
- 34 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Malignant Solid Tumour
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion weekly.
- Trial name
- NCT00388427
- Testing
- Dasatinib (BMS-354825), Cetuximab (Erbitux, C225)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Pittsburgh
Leukemia
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This study assesses the long-term safety and tolerability of dasatinib administered to patients with chronic myelogenous leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia and experienced clinical benefit…
- Trial name
- START rollover (NCT00982488)
- Testing
- Dasatinib, Imatinib
- Where
- 72 sites in United States, Argentina and 22 more
- Volunteers
- 238 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or…
- Trial name
- NCT00700882
- Testing
- dasatinib
- Where
- 153 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eastern Cooperative Oncology Group